Abstract

PurposeSubcutaneous immunoglobulin replacement therapy (IgRT) may be administered once a week with a pump or every other day with a syringe (rapid push). The objective of the study was to compare the impact of pump and rapid push infusions on patient’s life quality index (LQI).MethodsThis study was a randomized, crossover, multicenter, non-inferiority trial conducted in adults with primary immunodeficiency (PID) accustomed to weekly infusions at home by pump. Patients used pump or rapid push for 3 months each according to the randomized sequence. Main criterion was PID-LQI factor I (treatment interference). Non-inferiority ratio was set at 90%.ResultsThirty patients entered the study; 28 completed the two periods. IgRT exposure was similar during each period. At the end of each period, mean LQI factor 1 was 87.0 (IC95% [80.3; 94.3]) and 77.80 (IC95% [71.5; 84.7]) for pump and rapid push, respectively. There was a slightly larger effect of rapid push on treatment interference than with pump so that the primary endpoint could not be met. No difference was found on other LQI components, satisfaction (TSQM), or quality of life (SF36v2). Eight patients declared to prefer rapid push while 19 others preferred pump. Of rapid push infusions, 67.2% led to local reactions vs 71.8% of pump infusions (p = 0.11) illustrating its good tolerance. Rapid push and pump infusions achieved similar trough IgG levels with similar incidence of infections. Rapid push saved 70% of administration cost when compared to pump.ConclusionsSince IgRT is a lifelong treatment in PID patients, individualization of treatment is of paramount importance. Rapid push is a new administration method in the physician’s armamentarium which is preferred by some patients and is cost-effective.ClinicalTrials.gov IdentifierNCT02180763Clinical ImplicationsSelf-administration of small volumes of immunoglobulins at home, every other day, using a syringe (rapid push) is a cost-effective alternative to administration of larger volumes by pump once a week.Capsule SummaryThis study compared subcutaneous infusions of immunoglobulins either weekly via a pump or every other day via a syringe (rapid push). Rapid push is preferred by some patients and is cost-effective, therefore completing a physician’s armamentarium.

Highlights

  • More than 50% of primary immunodeficiencies (PIDs) are characterized by an altered antibody production [1], exposing the patients to an increased risk of repeated and severe infections [2]

  • The PID-life quality index (LQI) questionnaire involves 15 items rated on a 7-point Likert scale ranging from “Extremely Good” to “Extremely Poor.”

  • Since costs for Immunoglobulin replacement therapy (IgRT) are entirely covered by the French Social Insurance System, two questions related to economic concerns were deleted

Read more

Summary

Introduction

More than 50% of primary immunodeficiencies (PIDs) are characterized by an altered antibody production [1], exposing the patients to an increased risk of repeated and severe infections [2]. Immunoglobulin replacement therapy (IgRT) restores sufficiently high serum levels of IgG, decreases the incidence of infections [3], prevents complications such as bronchiectasis, and improves patient’s quality of life [4]. IgRT is administered intravenously (IVIg) or subcutaneously (SCIg). SCIg infusion achieves IgG trough levels and an efficacy similar to those of IVIg infusion but with lower incidence of general reactions [4], better health-related quality of life, higher patient’s satisfaction [5,6,7], and faster functional recovery with less time off work [8, 9]. Patients use an infusion pump and selfadminister SCIg once a week. SCIg by pump takes 1 to 2 h even with several catheters infusing several sites all at once

Objectives
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call